Tempest Therapeutics
TPST • NASDAQ
Tempest Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Matthew Angel, with a market cap of $23.3M.
CEOMatthew Angel
Next Earnings
Upcoming earnings announcement for Tempest Therapeutics
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.28
Earnings History
Past 12 earnings reports for Tempest Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Q4 2025 | -$0.62Est: -$0.62 | 0.0% | - | — |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.79Est: -$3.27 | +75.8% | - | — | 10-Q |
| Aug 11, 2025 | Q2 2025 | -$2.07Est: -$2.88 | +28.1% | - | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$3.16Est: -$0.31 | -919.4% | - | — | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.39Est: -$0.25 | -56.0% | - | — | 10-K/A |
| Nov 12, 2024 | Q3 2024 | -$0.41Est: -$0.35 | -17.1% | - | — | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.42Est: -$0.40 | -5.0% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.36Est: -$0.39 | +7.7% | - | — | 10-Q |
| Mar 19, 2024 | Q4 2023 | -$0.34Est: -$0.39 | +12.8% | - | — | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.48Est: -$0.57 | +15.8% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.54Est: -$0.52 | -3.8% | - | — | — |
| May 10, 2023 | Q1 2023 | -$0.55Est: -$0.64 | +14.1% | - | — | — |